The University of Queensland

Disclosed herein is a method of identifying an arrhythmogenic pluripotent stem cell-derived cardiomyocyte (PSC-CM), the method comprising: (i) determining whether CD200 is expressed on a surface of the PSC-CM; wherein if CD200 is expressed on the surface of the PSC-CM, the PSC-CM is an arrhythmogenic PSC-CM.

The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for inhibiting Class IIa versus Class I HDACs. The present application also relates to methods of using the compounds and to uses of the compounds, especially in relation to the prevention of a disease, disorder or condition associated with Class IIa HDAC activity. In one form, the compounds are (ortho-phenyl) phenyl hydroxamates. In another form, the compounds are as provided in Formula (I), wherein R1 is a phenyl or cycloalkenyl which may be optionally substituted. Formula (I)

An optical path monitoring process, including the following steps executed by a first node of an optical network: (i) generating photons that are at least partially indistinguishable in frequency, polarization, spatial mode and temporal profile; (ii) transmitting a first photon of the generated photons to a remote node of the optical network over an optical path; (iii) receiving the first photon from the remote node over an optical path; and (iv) interfering the received first photon with a second photon of the generated photons to generate a quantum interference visibility output; and (v) assessing physical integrity of the optical path(s) on the basis of the quantum interference visibility output.

A phononic circuit component including a membrane coupled to a substrate, the membrane including a region having an array of holes and a channel provided in the substrate beneath the region so that the region is released from the substrate, thereby allowing the region to propagate transverse acoustic waves, wherein the holes are spaced by a distance that is substantially smaller than a wavelength of the acoustic waves.

A composition for patterning substrates includes a monomer. The monomer includes a polymerizable unit, a thermally or photochemically activatable crosslinking structure, and an acid-cleavable de-crosslinking structure. The polymerizable unit includes an olefin.

A method and a system for removing a portion of at least one contaminant gas from a gas stream is disclosed. The method comprises the steps of: a) applying a voltage across a pair of electrodes in contact with a working fluid to generate a plurality of ions; and b) reacting the at least one contaminant gas with the plurality of ions to convert it to one or more reaction products, thereby sequestering at least some of the contaminant gas from the first gas stream to produce a second gas stream, wherein the pH of the working fluid is substantially maintained at a predetermined set point for improving the efficiency of the conversion. The invention also relates to a process for treating sewage or wastewater by adding the one or more reaction products to: the sewage, wastewater, sludge and/or an anaerobic digester.

An apparatus ( 40 ) for deaerating a froth comprising a spinning basket ( 44 ) mounted on a driven shaft ( 46 ). The side walls of the spinning basket have a mesh or openings therein. Froth is supplied to the interior of the spinning basket and contacts the floor of the spinning basket and is flung outwardly through the mesh or openings to break the bubbles and deaerate the froth. A solid wall ( 42 ) may surround the spinning basket to further assist in deaeration. A spinning plate may be used in place of the spinning basket. In another embodiment, vacuum is used to deaerate the froth.

A method for stratifying severity of asthma of a patient initially comprises receiving acoustic data corresponding to sounds of the patient from an acoustic sensor and identifying, by a processor, at least one cough sound in the acoustic data. With or without the patient being present, the method further involves determining, by operation of the processor, one or more overall cough sound feature values of the at least one cough sound for each of one or more characteristic features. The overall cough sound feature values are then applied to a classifier that is implemented by the processor and which has been pre-trained with a training set of characteristic feature values from a population of asthmatic and non-asthmatic subjects. The method then involves monitoring an output from the pre-trained classifier to deem the patient cough sound as indicating one of a number of degrees of severity of asthma.

This disclosure relates to methods of treating, preventing, or reversing inflammation-associated central nervous system (CNS) disorders or conditions comprising administering an effective amount of a Janus kinases (JAK) inhibitor such as baricitinib to a patient in need thereof. In certain embodiments, the CNS associated inflammatory disorder is depression, treatment resistant depression, fatigue, or cognitive dysfunction.

Disclosed are methods of genetic engineering to manipulate gene copy number in vivo, as well genetic constructs for amplifying gene copy number in vivo, and recombinant cells that comprise amplified genes. The methods of increasing gene copy number involve reducing expression levels of a haploinsufficient gene in the genome of recombinant cells, such as through replacing the endogenous promoter with a weaker promoter.